Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by Araim Pharmaceuticals, Inc.
Sponsor:
Information provided by (Responsible Party):
Araim Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT02039687
First received: January 16, 2014
Last updated: January 23, 2014
Last verified: January 2014
  Purpose

The purpose of this study is to determine whether ARA 290, a new class of compound, is effective in the treatment of the neuropathic symptoms of sarcoidosis. Brief interaction of ARA 290 with the innate repair receptor results in anti-apoptotic and anti-inflammatory activities in myriad of cells, tissues and organs throughout the body to activate repair mechanisms and accelerate healing, including the nerve damage that can be associated with sarcoidosis. In this study, subjects with sarcoidosis and symptoms of small fiber neuropathy will administered ARA 290 or placebo by subcutaneous injection daily for 28 days. In addition to monitoring the safety of the treatment, the symptoms of the subjects will be assessed with several questionnaires, function tests, and measurement of nerve fibers in their cornea and skin (via a non-invasive test and a biopsy, respectively). The total participation time for each patient will be 16 weeks.


Condition Intervention Phase
Neuropathy of Sarcoidosis
Drug: ARA 290
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double Blind, Placebo Controlled Phase 2 Dose Ranging Study of the Effects of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis

Resource links provided by NLM:


Further study details as provided by Araim Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • change in corneal nerve fiber density [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Measurement of corneal nerve fiber density is a non-invasive procedure performed at baseline and at the end of dosing and at 12 weeks follow-up. The nerve fiber density in sarcoidosis patients is reduced compared to normal humans, a measurement of small fiber loss.


Secondary Outcome Measures:
  • Change in the 6 minute walk test [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Measurement of the distance a patient can walk in 6 minutes

  • • Frequency of adverse events, serious adverse events, and laboratory parameters [ Time Frame: 16 weeks ] [ Designated as safety issue: Yes ]
  • • Change in the scores of the Small Fiber Neuropathy Screening List, BPI, NPSI, RAND-36, and FAS questionnaires [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    Patient reported pain level, function, and quality of life questionnaires

  • Intra-epidermal nerve fiber density [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Measurement of small fiber density in skin biopsies. Density is reduced in sarcoidosis patients, an indication of neuropathy.


Estimated Enrollment: 64
Study Start Date: January 2014
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 mg per day ARA 290
1 mg ARA 290 administered subcutaneously for 28 consecutive days
Drug: ARA 290
A small peptide that activates the innate repair receptor to induce anti-inflammatory and tissue repair mechanisms.
Experimental: 4 mg per day ARA 290
4 mg ARA 290 administered subcutaneously for 28 consecutive days
Drug: ARA 290
A small peptide that activates the innate repair receptor to induce anti-inflammatory and tissue repair mechanisms.
Experimental: 8 mg per day ARA 290
8 mg ARA 290 administered subcutaneously for 28 consecutive days
Drug: ARA 290
A small peptide that activates the innate repair receptor to induce anti-inflammatory and tissue repair mechanisms.
Placebo Comparator: placebo
1 mL placebo administered subcutaneously for 28 consecutive days

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

• Established diagnosis of sarcoidosis with both of the following two criteria:

  1. Score of 4 or greater on Brief Pain Inventory "pain now" or "average pain" questions (BPI; 0 (least discomfort)-10 (worst discomfort))
  2. Discomfort defined as distal pain/discomfort plus one of the following: 1) dysesthesia, 2) burning/painful feet worsening at night, or 3) intolerance of sheets or clothes touching the legs or feet

AND either of the following two criteria

  1. Corneal nerve fiber density reduced compared to normal (i.e., greater than 1 standard deviation less than the mean of a normative population)
  2. A previous skin biopsy (obtained within the prior 2 years) showing a reduced intraepidermal nerve fiber density ((i.e., greater than 1 standard deviation less than the mean of a normal age and gender relevant population)

In addition, subjects must:

  • Be able to read and understand the written consent form, complete study-related procedures, and communicate with the study staff
  • Be willing to comply with study restrictions
  • Be willing to check in with the study center via the telephone
  • Between 18 and 70 years of age (inclusive)
  • Body Mass Index (BMI) < 40 kg/m2 (inclusive)
  • If female of childbearing potential, a negative urine pregnancy test at screening and acceptable contraception will be maintained during the screening and dosing period and 1 month beyond. Acceptable contraception consists of hormonal methods such as oral, implantable, injectable, or transdermal contraceptives for a minimum of 1 full cycle (based on the subject's usual menstrual cycle period) before study entry, intrauterine device (IUD), or double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream).
  • Able to complete self-administered questionnaires (RAND-36, SFNSL, BPI, FAS, NPSI)
  • Refrigerator and freezer at home for storage of study medication.

Exclusion Criteria:

  • Clinically relevant abnormal history of physical and mental health other than conditions related to sarcoidosis, as determined by medical history taking (as judged by the investigator)
  • Clinically relevant abnormal laboratory results, vital signs, or physical findings other than conditions related to sarcoidosis or could interfere with conduct of 6-minute walk assessment (as judged by the investigator)
  • Other medical conditions known to be associated with small nerve fiber loss, except for diabetes in good control (as judged by the investigator)
  • Known clinically relevant abnormalities in ECG (as judged by the investigator)
  • Illicit drug abuse or excessive alcohol consumption (as judged by the investigator)
  • History of serious malignancy within the last 5 years other than a basal cell or squamous cell carcinoma of the skin that has been removed
  • History of severe allergies, or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food (as judged by the investigator)
  • Anti-TNF therapy, other biological anti-inflammatory agents, or immunoglobulins administered within the 3 months prior to screening.
  • Use of erythropoiesis stimulating agents within the two months prior to screening or during the trial
  • Participation in an investigational drug trial in the 3 months prior to administration of the initial dose of study drug or more than 4 times in the calendar year preceding study enrollment
  • Inadequate venous accessibility as judged by clinicians (physician or nurse)
  • Inability or unwillingness to self-administer ARA 290 via subcutaneous injections (or not have access to home health care for assistance in administration)
  • If female, pregnant or breast-feeding
  • Any other condition that in the opinion of the investigator would complicate or compromise the study, or the well-being of the subject
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02039687

Locations
United States, Ohio
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195
Contact: Daniel Culver, DO FCCP    216-444-6508    culverd@ccf.org   
Contact: Tani Martin, RN BSN CCRP    2194449975    martint5@ccf.org   
Principal Investigator: Daniel Culver, DO FCCP         
Netherlands
Leiden University Medical Center Recruiting
Leiden, Netherlands
Contact: Monique van Velzen, Ph.D.    +31 071 526 2301    m.van_velzen@lumc.nl   
Principal Investigator: Leon Aarts, MD PhD         
Sponsors and Collaborators
Araim Pharmaceuticals, Inc.
Investigators
Study Director: Micheal Brines, MD, PhD Araim Pharmaceuticals, Inc.
  More Information

No publications provided

Responsible Party: Araim Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT02039687     History of Changes
Other Study ID Numbers: APCP-112
Study First Received: January 16, 2014
Last Updated: January 23, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Araim Pharmaceuticals, Inc.:
neuropathy
sarcoidosis

Additional relevant MeSH terms:
Sarcoidosis
Lymphoproliferative Disorders
Lymphatic Diseases

ClinicalTrials.gov processed this record on August 26, 2014